Physician profile
Sandra Eastling
NPI 1770993420
$11,525.46
in general payments reported to CMS, 2019-2025
20 companies · $3,359 in 2025
The $3,359 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $2,128 · 2023: $766 · 2024: $4,779 · 2025: $3,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,273 · Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,272.81 |
| Food and Beverage | $1,630.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,813.68 | 2022-2025 | Nexplanon |
| Abbvie INC. | $436.75 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $338.89 | 2021-2024 | Breztri, Airsupra |
| Novo Nordisk INC | $245.58 | 2022-2024 | Wegovy |
| Medtronic, INC. | $187.14 | 2023 | Corevalve Evolut R, Interstim |
| Biohaven Pharmaceuticals, INC. | $129.81 | 2021 | |
| Daiichi Sankyo INC. | $122.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $122.79 | 2024 | Voquezna |
| Genzyme Corporation | $122.60 | 2023 | |
| Edwards Lifesciences Corporation | $122.18 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceutical Holding Company Ltd. | $114.77 | 2022 | |
| Alnylam Pharmaceuticals INC. | $106.10 | 2022 | |
| Mayne Pharma Commercial LLC | $103.73 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.33 | 2024 | Caplyta |
| Smith+Nephew, INC. | $97.74 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $96.94 | 2022 | |
| Dexcom, INC. | $94.18 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $77.67 | 2023 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.12 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Eastling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.